The advent of cancer immunotherapy, in which the host immune system is augmented to generate a personalized anti-tumor response, has transformed care for lung, melanoma, bladder, and kidney cancer patients. This has been accomplished using a variety of diverse but complementary strategies including: adoptive transfer of tumorinfiltrating lymphocytes (TILs), allogeneic cell-based vaccines, genetically-engineered autologous T-cells with chimeric antigen receptors (CARs), and immune checkpoint inhibition in which antibodies are used to overcome negative regulators of the adaptive immune response (eg, PD-1/PD-L1). These immune-based approaches have led to remarkable and durable remissions in many cancer patients with advanced disease who previously responded poorly to conventional treatments. 1, 2 Unfortunately, immune checkpoint inhibitors as single agents or in combination have shown limited activity against prostate cancer in clinical trials thus far. [3] [4] [5] [6] [7] Despite initial optimism, the lack of significant responses in the context of prostate cancer begs the question-why is prostate cancer different from other solid tumors, including many previously thought to be immunologically silent? MSCs are contributing to prostate cancer progression.
| Prostate cancer is characterized by t-cell exclusion

| Role of mesenchymal stem cells in cancer progression
Reciprocal interactions between the epithelium and stroma have long been appreciated to play important roles in such diverse physiological processes as embryonic patterning, differentiation, and normal tissue homeostasis, in addition to pathophysiological processes, including cancer initiation and progression. The latter is at least partially facilitated via inflammatory inducers and the suppression of immune surveillance, which occurs as a negative feedback response to chronic inflammation. Though the exact role of tumor-infiltrating MSCs in cancer progression is unclear and may be disease-specific, 36, 55 there is supporting evidence that they promote disease progression through multiple mechanisms, including stimulating angiogenesis, invasion, growth, survival, and the generation of carcinomaassociated fibroblasts (CAFs), in addition to suppression of the innate and adaptive anti-tumor immune response ( Figure 2 ). 36, [55] [56] [57] [58] CAFs are derived from MSCs and are also associated with significant pro-tumorigenic properties. [59] [60] [61] [62] This suggests that MSCs sit at a critical node regulating multiple pro-tumorigenic pathways and that selectively targeting this tumor-infiltrating population may have significant anti-tumor effects.
| Mesenchymal stem cells as mediators of immunosuppression
MSCs have well-documented immunomodulatory properties with numerous effects on the innate and adaptive immune system. 36, [63] [64] [65] [66] [67] The effects on the innate immune system include inhibition of NK cell proliferation and cytotoxicity, suppression of mast cell degranulation, promoting M2 polarization in macrophages (ie, TAMs), and blocking dendritic cell (DC) maturation and antigen presentation. ProLong Gold (ThermoFisher Scientific; Waltham, MA). Antibody specificity was previously documented using shRNA controls to the respective antibody targets. Slide images were captured using a Nikon 50i epifluorescence microscope equipped with X-Cite series 120
illuminator using a 40X/0.95 NA PlanApo lens with correction collar.
| T-cell suppression assay
PBMCs were labeled with CellTrace Violet (CTV) according to the manufacturer's instructions (BD Biosciences; San Jose, CA). CTV- 
| Constitutive and inducible expression of PD-L1 and PD-L2
The respective cultures were incubated in the presence or absence of 
| RESULTS
MSCs have previously been identified in radical prostatectomy tissue based upon the analytical and functional characteristics described above. 37, 38, 51 Of note, a subset of these patients had elevated numbers of MSCs in their prostates (∼1% of all cells in the tumor) based on multiparameter flow cytometry; an observation that does not correlate with Gleason score. 38 Furthermore, rather than the expected Gaussian distribution, a bimodal pattern was observed with ∼10-15% of cases in this MSC-enriched fraction ( Figure 3A) , suggesting that quantification of tumor-infiltrating MSCs may have prognostic value independent of
Gleason score. We have recently confirmed that MSCs are present in human prostate cancer tissue using independent methodology-that 87 and that MSCs are critical components regulating the metastatic niche. [88] [89] [90] The ongoing recruitment of MSCs to tumor tissue also raises the possibility of exploiting this inherent tumor tropism to develop a cell-based drug delivery vector. 36, 91, 92 MSCs are rapidly selected for in primary prostate stromal cultures derived from benign and malignant human tissue. 62 Figure 5A and C). Intriguingly, PrCSCs only robustly express PD-L2 at baseline, but can also upregulate both PD-L1 and PD-L2 under the same pro-inflammatory conditions ( Figures 5B and D) . In general, expression of these ligands by PrCSCs is comparable to or higher than that observed on bone marrow-derived
MSCs. LNCaP and PC3 prostate cancer cells were used as additional controls, which were consistent with previously documented baseline and inducible expression patterns for these checkpoints ( Figure 5E ). 93 These studies do not delineate the relative contributions of cell-cell interactions as opposed to soluble factors in mediating PrCSCdependent suppression of T-cell proliferation, but this relationship along with detailed mechanistic analyses are being explored in ongoing studies.
| DISCUSSION
The physiological relevance of the immunosuppressive activity of were unable to induce vessel sprouting in this assay. 51 In addition to restoring immune recognition, these observations suggest that selective depletion of tumor-infiltrating MSCs will also limit the production of required pro-angiogenic factors within the tumor microenvironment to suppress tumor growth. Inactivation of cyclin-dependent kinase (CDK)-12 was also recently documented to identify a distinct subset of advanced prostate cancer patients characterized by increased neo-antigen burden and T-cell infiltration who may benefit from immune checkpoint inhibition. 
| Potential for therapeutic targeting
